Drug Profile

SKB 107

Alternative Names: 177Lu-DOTA-Ibandronic acid; Lutetium-177 DOTA ibandronic acid; SKB-107; TBM-001

Latest Information Update: 01 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator The Affiliated Hospital of Southwest Medical University
Developer Sichuan Kelun-Biotech Biopharmaceutical
Class Antineoplastics; Drug conjugates; Radiopharmaceuticals; Small molecules
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Aug 2025 Phase-I clinical trials in Bone metastases in China (Parenteral), before August 2025 (Sichuan Kelun-Biotech Biopharmaceutical pipeline, August 2025)
01 Aug 2025 Sichuan Kelun-Biotech Biopharmaceutical plans a phase Ia/b trial for Bone metastases (Late-stage disease) in China (Parenteral), in August 2025 (NCT07087197)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com